Filing Flows

Filing Flows › 8-K events › Celularity

Celularity: other events

Form 8-K filed Oct 29, 2026 · items 8.01

FDA decisionsCelularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States

What the filing says

Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States Celularity to serve as the exclusive partner for the finish manufacturing of Vesalius’s Peptual peptide APIs, supporting Vesalius’s expansion into pharmaceutical ingredient supply

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Celularity at a glance

Latest quarterQ2 2026
Revenue$5.4M
Revenue Y/Y-5%
Operating margin-78.0%
IndustryPharmaceutical Preparations

Celularity, Q2 2026: revenue $5.4M (-5% year over year), operating margin -78.0%. The chart follows the revenue to costs, profit and cash.

Celularity: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.